Sosei Group

Japanese biopharmaceutical company that develops and commercializes innovative drugs..

Launch date

Jun 1990

Employees

Market cap

Enterprise valuation

€957m (Public information from Sep 2024)

Tokyo Japan (HQ)

https://soseiheptares.com/

https://twitter.com/soseiheptaresco https://www.linkedin.com/company/soseiheptaresco/

Corporate Venture Fund: Sosei CVC

Revenues, earnings & profits over time

JPY	2019	2020	2021	2022	2023	2024	2025
Revenues	9.7b	8.8b	17.7b	15.6b	12.8b	4.9b	5.2b
% growth	239 %	(9 %)	100 %	(12 %)	(18 %)	(62 %)	7 %
EBITDA	2.5b	3.6b	5.3b	5.0b	(5.7b)	-	-
% EBITDA margin	26 %	40 %	30 %	32 %	(45 %)	-	-
Profit	1.4b	1.5b	1.0b	382m	(7.2b)	-	-
% profit margin	15 %	17 %	6 %	2 %	(56 %)	-	-
R&D budget	4.3b	3.8b	5.9b	7.5b	10.1b	-	-
R&D % of revenue	44 %	43 %	33 %	48 %	79 %	-	-

Date	Investors	Amount	Round
-	Scottish Equity Partners Omega Funds	N/A	-
Aug 2003	Nomura Japan Asia Investment Mitsui Global Investment JAFCO Japan Yasuda Enterprise Development Resona Capital	$13.0m	Series B
Aug 2004	N/A	N/A	IPO
Sep 2004	N/A	£29.0m	Post IPO Equity
Mar 2012	JAFCO Japan	N/A	Post IPO Equity
Jul 2020	N/A	$200m	Post IPO Convertible
Total Funding		€11.8m

Tech stackLearn more about the technologies and tools that this company uses.

MiNA Therapeutics

Heptares Therapeutics

ACQUISITION by Sosei Group Feb 2015

ACQUISITION by Sosei Group Jul 2005

ACQUISITION Apr 2021